NVS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz...

Stats
Dzisiejszy wolumen	1.46M
Średni wolumen	1.63M
Kapitalizacja rynkowa	190.64B
EPS	$0 ( 2024-04-23 )
Następna data zysków	( $1.850 ) 2024-07-16
Last Dividend	$3.47 ( 2023-03-09 )
Next Dividend	$0 ( N/A )
P/E	22.15
ATR14	$0.0230 (0.02%)

Wolumen Korelacja

Długi: -0.67 (moderate negative)

Krótki: -0.82 (strong negative)

Signal:(23.382) Be Aware. Possible trading coming up! (swing)

Novartis AG Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novartis AG Korelacja - Waluta/Towar

-0.50
( neutral )

-0.77
( moderate negative )

0.00
( neutral )

-0.46
( neutral )

-0.29
( neutral )

-0.38
( neutral )

Novartis AG Finanse

Annual	2023
Przychody:	$46.66B
Zysk brutto:	$34.19B (73.27 %)
EPS:	$7.15

FY	2023
Przychody:	$46.66B
Zysk brutto:	$34.19B (73.27 %)
EPS:	$7.15

FY	2022
Przychody:	$51.83B
Zysk brutto:	$36.34B (70.12 %)
EPS:	$3.19

FY	2021
Przychody:	$52.88B
Zysk brutto:	$37.01B (69.99 %)
EPS:	$10.71

Financial Reports:

No articles found.

Novartis AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$3.47 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novartis AG Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.42 - Stable (8.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.966	2000-11-14
Last Dividend	$3.47	2023-03-09
Next Dividend	$0	N/A
Payout Date	2023-03-20
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	$44.60	--
Avg. Dividend % Per Year	2.46%	--
Score	4.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.42
Div. Directional Score	7.88	--

Next Divdend (Est)
(2025-01-10)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

4.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	$0.966	2.96%
2001	$0.450	1.12%
2002	$0.468	1.46%
2003	$0.627	1.89%
2004	$0.722	1.57%
2005	$0	0.00%
2006	$0.801	1.50%
2007	$0.969	1.67%
2008	$1.319	2.42%
2009	$1.541	3.11%
2010	$1.780	3.38%
2011	$2.11	3.56%
2012	$2.20	3.78%
2013	$2.27	3.56%
2014	$2.44	3.10%
2015	$2.52	2.73%
2016	$2.47	2.88%
2017	$2.46	3.38%
2018	$2.67	3.15%
2019	$2.57	3.06%
2020	$3.04	3.20%
2021	$3.38	3.58%
2022	$3.36	3.82%
2023	$3.47	3.76%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.307	1.500	3.86	5.79	[0 - 0.5]
returnOnAssetsTTM	0.162	1.200	4.61	5.54	[0 - 0.3]
returnOnEquityTTM	0.346	1.500	7.27	10.00	[0.1 - 1]
payoutRatioTTM	0.342	-1.000	6.58	-6.58	[0 - 1]
currentRatioTTM	0.903	0.800	-0.485	-0.388	[1 - 3]
quickRatioTTM	0.613	0.800	-1.102	-0.881	[0.8 - 2.5]
cashRatioTTM	0.323	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.273	-1.500	5.45	-8.17	[0 - 0.6]
interestCoverageTTM	12.32	1.000	6.55	6.55	[3 - 30]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.96	2.00	7.52	10.00	[0 - 20]
debtEquityRatioTTM	0.649	-1.500	7.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.726	1.000	1.237	1.237	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.61	7.61	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.534	1.000	8.14	8.14	[0.2 - 2]
assetTurnoverTTM	0.526	0.800	9.83	7.86	[0.5 - 2]
Total Score				10.33

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.06	1.000	8.78	0	[1 - 100]
returnOnEquityTTM	0.346	2.50	8.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.96	2.00	8.35	10.00	[0 - 30]
dividendYielPercentageTTM	3.88	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
payoutRatioTTM	0.342	1.500	6.58	-6.58	[0 - 1]
pegRatioTTM	-3.02	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.277	1.000	5.57	0	[0.1 - 0.5]
Total Score				5.42

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.